Skip to main content
. Author manuscript; available in PMC: 2016 May 11.
Published in final edited form as: J Clin Immunol. 2010 Sep 28;31(1):39–50. doi: 10.1007/s10875-010-9464-8

Appendix Table II.

Clinical characteristics of other CTCL subtypes.

Lymphoma Subtype No. Subjects (with stage) Average Age (yrs) Gender
CD8+ 2 (both IB) 63.5 2F
CD30+ 2 (IB, IIB) 57.5 2M
Non-Hodgkins 2 (IB, III) 68 2M
Peripheral T cell 1 (deceased) 74 1F
Totals 7 65.75 3F/4M
Controls 35 59.7 13F/22M

According to the World Health Organization (WHO) and the European Organization for Research and Treatment of Cancer (EORTC) combined staging classification. Table depicts patients’ stage at the time of enrollment.